Form Bio
- Company typePrivate
- Founded2022
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Form Bio firmographics
Firmographics- Name
- Form Bio
- Legal name
- Form Bio, Inc.
- Website
- https://formbio.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Form Bio industry classification
Industry- Product category
- Genetic Medicine Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Software Publishers (5132)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where Form Bio is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Form Bio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Platform-as-a-Service Subscription: Form Bio provides access to a platform-as-a-service that includes datasets, analytic workflows, algorithms, cloud-computing infrastructure, and scientific support. Access requires registration for user accounts and payment of applicable fees.
- FormManufacturing Services: AI-driven design optimization and genomic characterization services for genetic medicine manufacturing, combining FormSightAI and FormBatchQC for drug substance and manufacturing intelligence.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Platform access with separate agreement required |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Form Bio product offering
Product offeringCore offering
Form Bio provides an AI-driven platform for genetic medicine development and genome engineering, anchored by the FormManufacturing end-to-end system that combines the FormSightAI in silico vector design screening tool with the FormBatchQC lot-level genomic characterization service. The company sells platform subscriptions, codon optimization powered by the proprietary FORMsightAI model, and professional services for genome assembly, genome integrity analysis, protein engineering, and multiomic analysis to biotech and pharmaceutical companies developing cell and gene therapies.
Product overview
Form Bio is an AI-driven genetic medicine and genome engineering company that spun out from Colossal Biosciences in 2022. The company offers a comprehensive platform centered around FormManufacturing, which integrates AI-driven design (FormSightAI) with genomic characterization (FormBatchQC) to de-risk cell and gene therapy manufacturing. Additional offerings include codon optimization powered by the proprietary FORMsightAI model, genome assembly, genome integrity analysis, genome engineering, and protein engineering services. The platform provides solutions across drug substance insights, capsid analysis, bioinformatics analysis, gene editing, AI model development, and manufacturing intelligence for genetic medicine developers.
Differentiator
Problem solved
Functional benefit
Products and services
- FormManufacturing End-to-end platform that integrates AI-driven design optimization with deep genomic characterization to improve genetic medicine safety, efficacy, and manufacturability from discovery to commercial scale for biotech and pharmaceutical developers.
- FormSightAI
Quantifiable outcome
- 40% of IND submissions are delayed by CMC gaps
- +1 more outcomes
Companies that use Form Bio
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Form Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability7 records
Feature6 records
Form Bio partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and flagship.
- Cure Rare DiseasecorePartnership leverages AI-powered genome design to optimize AAV constructs, accelerate lead candidate selection, and improve drug substance manufacturability for rare and ultra-rare neuromuscular diseases including DMD program.
- Weill Cornell MedicinecoreStrategic collaboration to advance gene editing therapy for Alzheimer's disease. AI-powered vector design and preclinical validation mark first step in multi-phase program aimed at accelerating path from discovery to clinical assessment.
- Azenta Life SciencescoreStrategic partnership to advance AAV gene therapy development with integrated solution aimed at reducing time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster.
- PacBiocoreCollaboration to launch new resources and expert working group aimed at advancing and unifying the AAV industry. Includes AAV Resource Hub and working group to introduce essential tools for AAV development professionals.
- Google CloudcoreForm Bio harnesses Google Cloud for multiomic analysis platform built on Google Cloud's Multiomics Suite. Google Cloud's powerful AI models for healthcare and life sciences research available as point-and-click workflows via Form Bio's bioinformatics platform on Google Cloud Marketplace.
- Ginkgo BioworkscorePartnership to develop industry-leading solutions for AAV gene therapy design and development. Combined solution addresses critical hurdles in bringing gene therapy products to IND through collaborative design and development efforts.
- Colossal BiosciencesflagshipForm Bio is the first spinout from Colossal Biosciences (2022), which established the company's foundational multi-species genome engineering technology. Colossal's leadership including George Church, PhD serves as advisors. Colossal is Form Bio's trusted partner for genome engineering programs.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
Form Bio competitors and assessment
Company assessmentBroad incumbents
- Benchling: Benchling is a widely adopted cloud-based lab informatics platform serving biotech R&D, comparable to Form Bio's multiomic and bioinformatics analysis offering but as a horizontal platform rather than a genetic-medicine-specialized AI tool.
- Schrödinger: Schrödinger is a larger computational drug discovery platform offering physics-based and ML tools across multiple modalities, comparable to Form Bio's AI platform approach but with a broader, modality-agnostic portfolio.
Direct peers
- BigHat Biosciences: BigHat Biosciences applies AI/ML to antibody design and engineering, comparable to Form Bio's AI-driven sequence optimization and protein engineering capabilities for therapeutic development.
- Insitro: Insitro applies machine learning to drug discovery and development across multiple therapeutic modalities, comparable to Form Bio's AI-driven platform approach for genetic medicine design and characterization.
- AbCellera Biologics: AbCellera combines AI/ML with high-throughput antibody discovery, sharing the AI-augmented biologic engineering and platform-services business model that Form Bio applies to genetic medicines.
- Recursion Pharmaceuticals: Recursion operates a scaled AI-driven drug discovery platform combining high-throughput biology with machine learning, comparable to Form Bio's integrated AI plus wet-lab genetic medicine platform model.
- Generate Biomedicines: Generate Biomedicines is an AI-first generative biology company designing novel protein therapeutics using machine learning, directly comparable to Form Bio's AI-driven protein and genetic sequence design capabilities.
- Tessera Therapeutics: Tessera is a genetic medicines company developing gene writing technologies, directly comparable to Form Bio's genetic medicine and genome engineering focus area.
- Cradle Bio: Cradle uses generative AI and ML for protein engineering and design, directly comparable to Form Bio's AI-driven protein engineering offering under its protein engineering portfolio.
- Ginkgo Bioworks: Ginkgo Bioworks operates a synthetic biology and cell engineering platform, directly comparable to Form Bio's genome engineering capabilities and an existing strategic partner for AAV gene therapy development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Form Bio social profiles
Digital presenceForm Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Form Bio leadership team
Management profileNumber of profiles
Profiles9 records
Form Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Form Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Form Bio
What does Form Bio do?
Form Bio provides an AI-driven platform for genetic medicine development and genome engineering, anchored by the FormManufacturing end-to-end system that combines the FormSightAI in silico vector design screening tool with the FormBatchQC lot-level genomic characterization service. The company sells platform subscriptions, codon optimization powered by the proprietary FORMsightAI model, and professional services for genome assembly, genome integrity analysis, protein engineering, and multiomic analysis to biotech and pharmaceutical companies developing cell and gene therapies.
Is Form Bio a public or private company?
Form Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Form Bio founded?
Form Bio was founded in 2022. It employs 11 to 50 people.
Where is Form Bio based?
Form Bio is headquartered in San Francisco, United States, in the North America region.
How does Form Bio make money?
Two revenue lines are on record. Platform-as-a-Service Subscription is the primary driver. The others are formManufacturing Services.
Who are Form Bio's main competitors?
Broad incumbents on record are Benchling and Schrödinger. Direct peers are BigHat Biosciences, Insitro, AbCellera Biologics, Recursion Pharmaceuticals, Generate Biomedicines, Tessera Therapeutics, Cradle Bio and Ginkgo Bioworks.
Does Form Bio have an API?
No public API is recorded for Form Bio.
What industry is Form Bio in?
Form Bio's product category is Genetic Medicine Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 541714 and its SIC code is 8731.